Please check your internet connection and try again.
# Piperacillin/Tazobactam (Zosyn)
## Overview
Piperacillin/tazobactam is a penicillin-class drug combined with a beta-lactamase inhibitor. It has broad-spectrum activity against many gram-positive, gram-negative, and anaerobic bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections (including diabetic foot infections)
* Community-acquired pneumonia
* Hospital-acquired pneumonia (including ventilator-associated pneumonia)
* Empiric treatment of febrile neutropenia
## Adult Dosing
The typical dose is 3.375 grams every 6 hours or 4.5 grams every 8 hours, administered intravenously (IV) over 30 minutes. The choice between these regimens often depends on institutional protocol and specific clinical indications (e.g., severe infections or hospital-acquired pneumonia may favor the 4.5 gram every 8-hour regimen). Higher doses may be used for severe infections.
## Pediatric Dosing
Dosing is based on piperacillin weight.
* **Neonates and infants up to 12 months:** 80 mg piperacillin/10 mg tazobactam per kg per dose IV every 8 to 12 hours, depending on gestational and postnatal age.
* **Children 1 to 12 years:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose IV every 8 hours.
* Maximum dose: Generally not to exceed the adult dose of 4.5 grams every 8 hours.
## Dose Adjustments
* **Renal Impairment (CrCl < 20 mL/min):** Reduce dose frequency. For 3.375 g Q6H, administer 2.25 g Q8H. For 4.5 g Q8H, administer 3.375 g Q12H. Dosing for CrCl 20-50 mL/min may also require adjustment per institutional guidelines. Hemodialysis patients require dose adjustment and an additional dose after each dialysis session.
* **Hepatic Impairment:** No specific dose adjustment is typically recommended, but caution is advised.
## Contraindications
* Known hypersensitivity to piperacillin, tazobactam, other penicillin antibiotics, or any component of the formulation.
## Adverse Effects
Common: Diarrhea, rash, nausea, vomiting, headache, insomnia, fever, injection site reactions.
Serious: *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures (especially with high doses or renal impairment), interstitial nephritis, hepatotoxicity, neutropenia, thrombocytopenia.
## Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin/tazobactam serum concentrations.
* **Aminoglycosides:** Generally compatible, but co-administration may lead to reduced efficacy for *Pseudomonas aeruginosa* in some settings. Avoid IV co-administration if possible; administer separately.
* **Neuromuscular Blocking Agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** May decrease the effect of warfarin, requiring increased monitoring of INR.
* **Methotrexate:** Piperacillin may decrease methotrexate clearance; monitor methotrexate levels.
## Monitoring
* Renal and hepatic function.
* Signs and symptoms of hypersensitivity reactions.
* Signs and symptoms of *C. difficile* infection.
* Complete blood count (CBC) with differential, particularly with prolonged therapy.
* Electrolytes.
* INR if the patient is on warfarin.
## Clinical Pearls
* Ensure adequate hydration to minimize the risk of neurotoxicity.
* Reconstituted solutions should be used within specified stability times.
* Consider the susceptibility patterns of local pathogens when initiating therapy.
* Tazobactam does not extend the spectrum of activity against bacteria that are intrinsically resistant to piperacillin.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and institutional guidelines for the most current and comprehensive recommendations. Dosing may vary based on patient-specific factors and local protocols.*
